marketcaparena
Search

    BMRA

    BIOMERICA INC

    Company overview

    Market capitalization
    $10.99M
    Employees
    53
    Latest publication
    2026-09-29
    About BIOMERICA INC

    Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

    Company website

    Financial statements

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-05-31 · USDFY 20252025-05-31 · USDFY 20242024-05-31 · USDFY 20232023-05-31 · USDFY 20222022-05-31 · USDFY 20212021-05-31 · USDFY 20202020-05-31 · USDFY 20192019-05-31 · USD
    Total Revenue4,453,000USD5,311,000USD5,415,000USD5,339,000USD18,871,409USD7,199,027USD6,692,711USD5,200,682USD
    Cost Of Revenue4,091,000USD4,813,000USD4,804,000USD4,893,000USD15,893,991USD6,832,742USD4,910,935USD3,908,668USD
    Gross Profit362,000USD498,000USD611,000USD446,000USD2,977,418USD366,285USD1,781,776USD1,292,014USD
    Research Development788,000USD1,023,000USD1,491,000USD1,584,000USD1,812,424USD2,194,461USD1,910,209USD1,679,098USD
    Selling General Administrative3,229,000USD4,612,000USD5,487,000USD6,085,000USD5,698,958USD4,608,950USD2,274,415USD2,025,706USD
    Selling And Marketing Expenses1,665,000USD———————
    General And Administrative Expenses3,229,000USD———————
    Total Operating Expenses5,682,000USD5,635,000USD6,978,000USD7,669,000USD7,511,382USD7,865,978USD4,184,624USD3,704,804USD
    Operating Income-5,320,000USD-5,137,000USD-6,367,000USD-7,223,000USD-4,533,964USD-7,499,693USD-2,402,848USD-2,412,790USD
    Total Other Income Expense Net1,568,000USD165,000USD431,000USD134,000USD26,639USD66,496USD71,184USD43,967USD
    Interest Income1,233,000USD165,000USD431,000USD133,000USD26,639USD66,863USD71,193USD44,014USD
    Income Before Tax-3,752,000USD-4,972,000USD-5,936,000USD-7,089,000USD-4,507,325USD-7,433,197USD-2,331,664USD-2,368,823USD
    Income Tax Expense23,000USD1,000USD42,000USD51,000USD23,719USD13,057USD7,390USD24,237USD
    Net Income-3,775,000USD-4,973,000USD-5,978,000USD-7,140,000USD-4,531,044USD-7,446,254USD-2,339,054USD-2,393,060USD
    Net Interest Income—165,000USD431,000USD133,000USD26,639USD66,496USD71,184USD43,967USD
    Tax Provision—1,000USD42,000USD51,000USD23,719USD13,057USD7,390USD24,237USD
    Net Income From Continuing Ops—-4,973,000USD-5,978,000USD-7,140,000USD-4,531,044USD-6,469,036USD-2,339,054USD-2,393,060USD
    Ebit—-5,137,000USD-6,367,000USD-7,223,000USD-4,533,821USD-7,433,200USD-2,331,665USD-2,368,826USD
    Ebitda—-4,737,000USD-5,993,000USD-6,872,000USD-3,939,000USD-7,057,345USD-1,933,033USD-2,205,921USD
    Depreciation And Amortization—400,000USD374,000USD351,000USD594,821USD375,855USD398,632USD162,905USD
    Reconciled Depreciation—400,000USD374,000USD351,000USD594,821USD375,855USD398,632USD162,905USD
    Net Income Applicable To Common Shares———-7,140,000USD-4,531,044USD-6,469,036USD-2,339,054USD-2,393,060USD
    Interest Expense————26,639USD367USD9USD47USD
    Unclassified Operating Expenses—————1,062,567USD——
    Non Operating Income Net Other—————66,863USD—44,014USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-02-28 · USDQ2 20262025-11-30 · USDQ1 20262025-08-31 · USDQ4 20252025-05-31 · USDQ3 20252025-02-28 · USDQ2 20252024-11-30 · USDQ1 20252024-08-31 · USDQ4 20242024-05-31 · USD
    Total Revenue987,000USD1,210,000USD1,380,000USD749,000USD1,119,000USD1,636,000USD1,807,000USD1,116,000USD
    Cost Of Revenue1,031,000USD1,159,000USD956,000USD993,000USD1,100,000USD1,199,000USD1,518,000USD1,096,000USD
    Gross Profit-44,000USD51,000USD424,000USD-244,000USD19,000USD437,000USD289,000USD20,000USD
    Research Development178,000USD193,000USD212,000USD252,000USD217,000USD257,000USD297,000USD265,000USD
    Selling General Administrative1,076,000USD1,231,000USD1,330,000USD1,068,000USD1,012,000USD1,173,000USD1,360,000USD1,283,000USD
    Total Operating Expenses1,254,000USD1,424,000USD1,542,000USD1,320,000USD1,229,000USD1,430,000USD1,657,000USD1,548,000USD
    Operating Income-1,298,000USD-1,373,000USD-1,118,000USD-1,564,000USD-1,210,000USD-993,000USD-1,368,000USD-1,528,000USD
    Interest Expense6,000USD———————
    Net Interest Income-6,000USD58,000USD1,123,000USD25,000USD43,000USD40,000USD56,000USD114,000USD
    Income Before Tax-1,304,000USD-1,315,000USD5,000USD-1,539,000USD-1,167,000USD-953,000USD-1,312,000USD-1,414,000USD
    Income Tax Expense8,000USD5,000USD3,000USD5,000USD-4,000USD-3,000USD4,000USD7,000USD
    Tax Provision8,000USD5,000USD3,000USD5,000USD-4,000USD-3,000USD4,000USD7,000USD
    Net Income-1,312,000USD-1,320,000USD2,000USD-1,544,000USD-1,163,000USD-950,000USD-1,316,000USD-1,421,000USD
    Net Income From Continuing Ops-1,312,000USD-1,320,000USD2,000USD-1,544,000USD-1,163,000USD-950,000USD-1,316,000USD-1,421,000USD
    Ebitda-1,298,000USD-1,212,000USD107,000USD-1,460,000USD-1,111,000USD-993,000USD-1,271,000USD-1,431,000USD
    Reconciled Depreciation105,000USD103,000USD102,000USD104,000USD99,000USD100,000USD97,000USD97,000USD
    Total Other Income Expense Net-6,000USD58,000USD1,123,000USD25,000USD43,000USD40,000USD56,000USD114,000USD
    Interest Income—58,000USD1,123,000USD25,000USD43,000USD40,000USD56,000USD114,000USD
    Ebit—-1,315,000USD5,000USD-1,564,000USD-1,210,000USD—-1,368,000USD-1,528,000USD
    Depreciation And Amortization—103,000USD102,000USD104,000USD99,000USD—97,000USD97,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ4 20262026-05-31 · USDQ3 20262026-02-28 · USDQ2 20262025-11-30 · USDQ1 20262025-08-31 · USDQ4 20252025-05-31 · USDQ3 20252025-02-28 · USDQ2 20252024-11-30 · USDQ1 20252024-08-31 · USD
    Total Assets6,759,000USD4,878,000USD6,034,000USD6,854,000USD5,945,000USD7,376,000USD7,274,000USD7,870,000USD
    Cash And Equivalents1,308,000USD———————
    Total Current Assets4,016,000USD4,123,000USD5,191,000USD5,899,000USD4,875,000USD6,204,000USD5,945,000USD6,445,000USD
    Other Current Assets216,000USD201,000USD177,000USD168,000USD255,000USD223,000USD458,000USD132,000USD
    Other Non Current Assets83,000USD———————
    Total Liabilities4,129,000USD———————
    Total Current Liabilities2,481,000USD1,561,000USD1,599,000USD1,693,000USD1,740,000USD1,649,000USD1,876,000USD2,151,000USD
    Other Current Liabilities794,000USD———————
    Total Stockholder Equity2,630,000USD3,317,000USD4,435,000USD5,155,000USD4,105,000USD5,534,000USD5,114,000USD5,346,000USD
    Total Equity Including Noncontrolling Interest2,630,000USD———————
    Net Receivables785,000USD941,000USD947,000USD1,205,000USD731,000USD1,268,000USD1,326,000USD1,551,000USD
    Inventory1,707,000USD1,645,000USD1,524,000USD1,473,000USD1,490,000USD1,655,000USD1,789,000USD1,942,000USD
    Property Plant Equipment Net1,951,000USD270,000USD369,000USD467,000USD564,000USD660,000USD755,000USD850,000USD
    Intangible Assets209,000USD231,000USD219,000USD223,000USD228,000USD234,000USD236,000USD207,000USD
    Accounts Payable377,000USD730,000USD740,000USD681,000USD295,000USD632,000USD—1,089,000USD
    Short Term Debt235,000USD193,000USD284,000USD367,000USD358,000USD350,000USD342,000USD334,000USD
    Common Stock255,000USD242,000USD236,000USD225,000USD203,000USD1,629,000USD1,467,000USD1,346,000USD
    Retained Earnings-56,943,000USD-55,798,000USD-54,486,000USD-53,166,000USD-53,168,000USD-51,624,000USD-50,461,000USD-49,511,000USD
    Accumulated Other Comprehensive Income-108,000USD-103,000USD-103,000USD-102,000USD-105,000USD-113,000USD-112,000USD-108,000USD
    Total Liab—1,561,000USD1,599,000USD1,699,000USD1,840,000USD1,842,000USD2,160,000USD2,524,000USD
    Other Current Liab—608,000USD545,000USD591,000USD1,032,000USD612,000USD1,449,000USD643,000USD
    Capital Stock—242,000USD236,000USD225,000USD203,000USD1,629,000USD1,467,000USD1,346,000USD
    Cash—1,336,000USD2,543,000USD3,053,000USD2,399,000USD3,058,000USD2,372,000USD2,820,000USD
    Cash And Short Term Investments—1,336,000USD2,543,000USD3,053,000USD2,399,000USD3,058,000USD2,372,000USD2,820,000USD
    Current Deferred Revenue—30,000USD30,000USD54,000USD55,000USD55,000USD85,000USD85,000USD
    Net Debt—-1,143,000USD-2,259,000USD-2,680,000USD-1,941,000USD-2,515,000USD-1,746,000USD-2,113,000USD
    Short Long Term Debt Total—193,000USD284,000USD373,000USD458,000USD543,000USD626,000USD707,000USD
    Long Term Investments—165,000USD165,000USD165,000USD165,000USD165,000USD165,000USD165,000USD
    Property Plant Equipment Gross—1,757,000USD1,772,000USD1,787,000USD3,247,000USD3,247,000USD3,247,000USD1,836,000USD
    Common Stock Shares Outstanding—3,010,308shares2,908,164shares2,638,699shares9,709,247shares17,121,436shares17,121,436shares16,821,646shares
    Non Current Assets Total—755,000USD843,000USD955,000USD1,070,000USD1,172,000USD1,329,000USD1,425,000USD
    Non Current Liabilities Total—0USD0USD6,000USD100,000USD193,000USD284,000USD373,000USD
    Non Currrent Assets Other—89,000USD90,000USD100,000USD113,000USD113,000USD173,000USD203,000USD
    Net Working Capital—2,562,000USD3,592,000USD4,206,000USD3,135,000USD4,555,000USD4,069,000USD4,294,000USD
    Unclassified Equity—58,734,000USD58,552,000USD57,973,000USD56,972,000USD54,013,000USD52,753,000USD52,273,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-05-31 · USDFY 20252025-05-31 · USDFY 20242024-05-31 · USDFY 20232023-05-31 · USDFY 20222022-05-31 · USDFY 20212021-05-31 · USDFY 20202020-05-31 · USDFY 20192019-05-31 · USD
    Total Assets6,759,000USD5,945,000USD9,254,000USD14,454,000USD11,374,280USD11,818,813USD17,259,878USD5,245,364USD
    Cash And Equivalents1,308,000USD———————
    Total Current Assets4,016,000USD4,875,000USD7,731,000USD12,797,000USD9,427,531USD9,230,907USD14,766,817USD4,494,929USD
    Other Current Assets216,000USD255,000USD238,000USD300,000USD320,730USD370,290USD1,509,083USD404,804USD
    Other Non Current Assets83,000USD———————
    Total Liabilities4,129,000USD———————
    Total Current Liabilities2,481,000USD1,740,000USD2,204,000USD1,945,000USD2,011,282USD1,300,220USD1,477,147USD1,264,394USD
    Other Current Liabilities794,000USD———————
    Total Stockholder Equity2,630,000USD4,105,000USD6,591,000USD11,724,000USD8,324,714USD9,227,023USD14,213,053USD3,980,970USD
    Total Equity Including Noncontrolling Interest2,630,000USD———————
    Net Receivables785,000USD731,000USD947,000USD722,000USD773,818USD1,455,051USD1,765,871USD1,454,652USD
    Inventory1,707,000USD1,490,000USD2,376,000USD2,056,000USD2,416,000USD3,206,000USD2,850,836USD2,151,090USD
    Property Plant Equipment Net1,951,000USD564,000USD943,000USD1,248,000USD1,515,474USD1,863,601USD1,990,889USD351,070USD
    Intangible Assets209,000USD228,000USD212,000USD165,000USD170,000USD294,830USD168,655USD107,209USD
    Accounts Payable377,000USD295,000USD288,000USD344,000USD736,000USD431,000USD833,412USD999,593USD
    Short Term Debt235,000USD358,000USD326,000USD297,000USD341,000USD327,944USD211,809USD—
    Common Stock255,000USD203,000USD1,346,000USD1,346,000USD1,029,432USD984,571USD939,205USD774,173USD
    Retained Earnings-56,943,000USD-53,168,000USD-48,195,000USD-42,217,000USD-35,077,379USD-30,546,335USD-21,925,732USD-19,586,678USD
    Accumulated Other Comprehensive Income-108,000USD-105,000USD-102,000USD-110,000USD-73,936USD-47,956USD-39,841USD-36,531USD
    Total Liab—1,840,000USD2,663,000USD2,730,000USD3,049,566USD2,591,790USD3,046,825USD1,264,394USD
    Other Current Liab—1,032,000USD1,505,000USD1,244,000USD883,282USD541,276USD431,926USD264,801USD
    Capital Stock—203,000USD1,346,000USD1,346,000USD1,029,432USD984,571USD964,919USD774,173USD
    Cash—2,399,000USD4,170,000USD9,719,000USD5,916,983USD4,199,311USD8,641,027USD686,785USD
    Cash And Short Term Investments—2,399,000USD4,170,000USD9,719,000USD5,916,983USD4,199,311USD8,641,027USD686,785USD
    Current Deferred Revenue—55,000USD85,000USD60,000USD51,000USD———
    Net Debt—-1,941,000USD-3,385,000USD-8,637,000USD-4,537,403USD-2,579,797USD-6,859,540USD-686,785USD
    Short Long Term Debt Total—458,000USD785,000USD1,082,000USD1,379,580USD1,619,514USD1,781,487USD—
    Long Term Investments—165,000USD165,000USD165,000USD165,324USD165,324USD165,324USD165,324USD
    Property Plant Equipment Gross—3,247,000USD3,247,000USD3,196,000USD3,545,636USD1,863,601USD1,990,889USD351,070USD
    Common Stock Shares Outstanding—2,297,057shares16,821,646shares14,154,269shares12,673,245shares11,928,941shares10,166,296shares9,212,557shares
    Non Current Assets Total—1,070,000USD1,523,000USD1,657,000USD1,946,386USD2,587,906USD2,493,061USD750,435USD
    Non Current Liabilities Total—100,000USD459,000USD785,000USD1,038,284USD1,291,570USD1,569,678USD999,593USD
    Non Currrent Assets Other—113,000USD203,000USD79,000USD95,588USD264,151USD168,193USD126,832USD
    Net Working Capital—3,135,000USD5,527,000USD10,852,000USD7,416,249USD7,930,687USD13,289,670USD3,230,535USD
    Unclassified Equity—56,972,000USD52,196,000USD51,359,000USD41,417,165USD37,852,172USD34,274,502USD22,055,833USD
    Other Assets———79,000USD363USD264,151USD168,193USD126,832USD
    Net Tangible Assets———11,559,000USD8,155,198USD8,932,193USD14,018,684USD3,873,761USD
    Unclassified Non Current Liabilities————1,038,284USD—1,569,678USD—
    Non Current Liabilities Other—————1,291,570USD——
    Accumulated Depreciation———————-1,762,344USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-05-31 · USDFY 20252025-05-31 · USDFY 20242024-05-31 · USDFY 20232023-05-31 · USDFY 20222022-05-31 · USDFY 20212021-05-31 · USDFY 20202020-05-31 · USDFY 20192019-05-31 · USD
    Depreciation77,000USD400,000USD374,000USD351,000USD594,821USD375,855USD398,632USD162,905USD
    Stock Based Compensation476,000USD460,000USD837,000USD1,185,000USD1,260,000USD1,354,609USD200,470USD151,224USD
    Change To Account Receivables-66,000USD209,000USD-215,000USD-291,000USD1,365,417USD-455,614USD-309,090USD-670,126USD
    Change To Inventory-140,000USD882,000USD-115,000USD534,000USD1,561,544USD-1,906,013USD-717,460USD21,387USD
    Change To Liabilities499,000USD——-80,000USD388,992USD-403,331USD-12,883USD360,971USD
    Change In Working Capital192,000USD268,000USD-625,000USD-38,000USD2,914,645USD-1,852,986USD-2,537,289USD-188,023USD
    Operating Cash Flow-3,421,000USD———————
    Investing Cash Flow-1,000USD———————
    Financing Cash Flow2,334,000USD———————
    Effect Of Forex Changes On Cash-3,000USD———————
    Change In Cash-1,091,000USD-1,770,000USD-5,549,000USD3,802,000USD1,717,672USD-4,441,716USD7,954,242USD-518,118USD
    End Cash Flow1,308,000USD———————
    Net Income—-4,973,000USD-5,978,000USD-7,140,000USD-4,531,044USD-7,446,254USD-2,339,054USD-2,393,060USD
    Other Non Cash Items—4,000USD31,000USD168,000USD-719,149USD3,671,637USD-37,971USD12,915USD
    Total Cash From Operating Activities—-3,841,000USD-5,361,000USD-5,474,000USD-480,532USD-5,251,748USD-4,297,498USD-2,244,039USD
    Capital Expenditures—-37,000USD-115,000USD-78,000USD-170,336USD-295,583USD-118,927USD-171,111USD
    Free Cash Flow—-3,878,000USD-5,476,000USD-5,552,000USD-650,868USD-5,547,331USD-4,416,425USD-2,415,150USD
    Investments—-37,000USD-115,000USD-78,000USD-170,336USD-295,583USD-118,927USD-171,111USD
    Total Cashflows From Investing Activities—-37,000USD-115,000USD-78,000USD-170,336USD-295,583USD-118,927USD-171,111USD
    Total Cash From Financing Activities—2,111,000USD-81,000USD9,390,000USD2,394,520USD1,113,730USD12,373,977USD1,907,427USD
    Issuance Of Capital Stock—2,143,000USD0USD10,014,000USD2,401,734USD1,011,475USD12,150,443USD1,776,575USD
    Begin Period Cash Flow—4,170,000USD9,719,000USD5,917,000USD4,199,311USD8,641,027USD686,785USD1,204,903USD
    End Period Cash Flow—2,400,000USD4,170,000USD9,719,000USD5,916,983USD4,199,311USD8,641,027USD686,785USD
    Other Cashflows From Financing Activities—-32,000USD-81,000USD81,000USD77,520USD102,255USD2,141,120USD130,852USD
    Sale Purchase Of Stock——0USD-705,000USD-85,000USD-165,919USD—1,898,365USD
    Other Cashflows From Investing Activities——-64,000USD-14,000USD-113,000USD-159,727USD-85,319USD-69,974USD
    Unclassified Financing Cash Flow———10,014,000USD2,402,000USD1,177,394USD-1,917,586USD—
    Exchange Rate Changes—————-8,115USD—-10,395USD
    Cash And Cash Equivalents Changes—————-4,441,716USD—-518,118USD
    Unclassified Operating Cash Flow—————-1,354,609USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-02-28 · USDQ2 20262025-11-30 · USDQ1 20262025-08-31 · USDQ4 20252025-05-31 · USDQ3 20252025-02-28 · USDQ2 20252024-11-30 · USDQ1 20252024-08-31 · USDQ4 20242024-05-31 · USD
    Net Income-1,312,000USD-1,320,000USD2,000USD-1,544,000USD-1,163,000USD-950,000USD-1,316,000USD-1,421,000USD
    Depreciation105,000USD103,000USD102,000USD104,000USD99,000USD100,000USD97,000USD97,000USD
    Stock Based Compensation135,000USD-210,000USD460,000USD108,000USD120,000USD155,000USD77,000USD204,000USD
    Other Non Cash Items-95,000USD315,000USD-282,000USD42,000USD-48,000USD-315,000USD17,000USD-28,000USD
    Change To Account Receivables64,000USD227,000USD-512,000USD536,000USD60,000USD229,000USD-616,000USD187,000USD
    Change To Inventory-84,000USD-8,000USD10,000USD116,000USD181,000USD156,000USD429,000USD-224,000USD
    Change In Working Capital-83,000USD121,000USD-550,000USD629,000USD-53,000USD219,000USD-219,000USD104,000USD
    Total Cash From Operating Activities-1,250,000USD-991,000USD-268,000USD-661,000USD-1,045,000USD-791,000USD-1,344,000USD-1,044,000USD
    Capital Expenditures-37,000USD-37,000USD0USD0USD-4,000USD0USD0USD-24,000USD
    Free Cash Flow-1,287,000USD-954,000USD-268,000USD-661,000USD-1,045,000USD-791,000USD-1,344,000USD-1,068,000USD
    Total Cashflows From Investing Activities-19,000USD37,000USD-37,000USD4,000USD-4,000USD-33,000USD-63,000USD-24,000USD
    Total Cash From Financing Activities61,000USD482,000USD920,000USD-5,000USD1,736,000USD380,000USD63,000USD-81,000USD
    Sale Purchase Of Stock19,000USD—-19,000USD————0USD
    Issuance Of Capital Stock63,000USD493,000USD939,000USD0USD1,751,000USD——0USD
    Change In Cash-1,207,000USD-473,000USD617,000USD-658,000USD686,000USD-448,000USD-1,350,000USD-1,141,000USD
    Begin Period Cash Flow2,543,000USD3,016,000USD2,399,000USD3,058,000USD2,372,000USD2,820,000USD4,170,000USD5,319,000USD
    End Period Cash Flow1,336,000USD2,543,000USD3,016,000USD2,400,000USD3,058,000USD2,372,000USD2,820,000USD4,170,000USD
    Other Cashflows From Investing Activities-19,000USD——-4,000USD-4,000USD-33,000USD-63,000USD—
    Other Cashflows From Financing Activities-2,000USD——-85,000USD-15,000USD24,000USD63,000USD-81,000USD
    Investments———0USD-4,000USD-33,000USD0USD-24,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2026Quarterly · 2026-02-28GeographyAsia270,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28GeographyEurope287,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28GeographyMiddle East171,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28GeographyNorth America259,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28ProductClinical Lab621,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28ProductContract Manufacturing167,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28ProductOver The Counte197,000USD0001493152-26-016388
    Q3 2026Quarterly · 2026-02-28ProductPhysicians Office2,000USD0001493152-26-016388
    Q2 2026Quarterly · 2025-11-30GeographyAsia358,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30GeographyEurope262,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30GeographyMiddle East137,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30GeographyNorth America443,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30GeographySouth America10,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30ProductClinical Lab676,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30ProductContract Manufacturing172,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30ProductOver The Counters361,000USD0001493152-26-002286
    Q2 2026Quarterly · 2025-11-30ProductPhysicians Office1,000USD0001493152-26-002286
    Q1 2026Quarterly · 2025-08-31GeographyAsia670,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31GeographyEurope305,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31GeographyMiddle East85,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31GeographyNorth America318,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31GeographySouth America2,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31ProductClinical Lab1,024,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31ProductContract Manufacturing192,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31ProductOver The Counters161,000USD0001493152-25-018043
    Q1 2026Quarterly · 2025-08-31ProductPhysicians Office3,000USD0001493152-25-018043
    Q4 2025Quarterly · 2025-05-31GeographyAsia105,000USDLegacy provider
    Q4 2025Quarterly · 2025-05-31GeographyEurope318,000USDLegacy provider
    Q4 2025Quarterly · 2025-05-31GeographyMiddle East50,000USDLegacy provider
    Q4 2025Quarterly · 2025-05-31GeographyNorth America276,000USDLegacy provider
    Q4 2025Quarterly · 2025-05-31GeographySouth America0USDLegacy provider
    FY 2025Yearly · 2025-05-31GeographyAsia1,718,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31GeographyEurope1,297,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31GeographyMiddle East630,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31GeographyNorth America1,658,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31GeographySouth America8,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31ProductClinical Lab3,181,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31ProductContract Manufacturing1,070,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31ProductOver The Counte1,049,000USD0001641172-25-026041
    FY 2025Yearly · 2025-05-31ProductPhysicians Office11,000USD0001641172-25-026041
    Q3 2025Quarterly · 2025-02-28GeographyAsia365,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28GeographyEurope198,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28GeographyMiddle East149,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28GeographyNorth America404,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28GeographySouth America3,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28ProductClinical Lab627,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28ProductContract Manufacturing320,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28ProductOver The Counte170,000USD0001493152-26-016388
    Q3 2025Quarterly · 2025-02-28ProductPhysicians Office2,000USD0001493152-26-016388
    Q2 2025Quarterly · 2024-11-30GeographyAsia431,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30GeographyEurope311,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30GeographyMiddle East341,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30GeographyNorth America551,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30GeographySouth America2,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30ProductClinical Lab777,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30ProductContract Manufacturing260,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30ProductOver The Counters596,000USD0001493152-26-002286
    Q2 2025Quarterly · 2024-11-30ProductPhysicians Office3,000USD0001493152-26-002286
    Q1 2025Quarterly · 2024-08-31GeographyAsia817,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31GeographyEurope470,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31GeographyMiddle East90,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31GeographyNorth America427,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31GeographySouth America3,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31ProductClinical Lab1,278,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31ProductContract Manufacturing339,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31ProductOver The Counters187,000USD0001493152-25-018043
    Q1 2025Quarterly · 2024-08-31ProductPhysicians Office3,000USD0001493152-25-018043
    Q4 2024Quarterly · 2024-05-31ProductClinical Lab551,000USDLegacy provider
    Q4 2024Quarterly · 2024-05-31ProductContract Manufacturing212,000USDLegacy provider
    Q4 2024Quarterly · 2024-05-31ProductOver The Counte351,000USDLegacy provider
    Q4 2024Quarterly · 2024-05-31ProductPhysicians Office4,000USDLegacy provider
    FY 2024Yearly · 2024-05-31GeographyAsia1,881,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31GeographyEurope1,438,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31GeographyMiddle East800,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31GeographyNorth America1,285,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31GeographySouth America11,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31ProductClinical Lab3,236,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31ProductContract Manufacturing741,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31ProductOver The Counte1,426,000USD0001641172-25-026041
    FY 2024Yearly · 2024-05-31ProductPhysicians Office12,000USD0001641172-25-026041
    Q3 2024Quarterly · 2024-02-29GeographyAsia210,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29GeographyEurope331,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29GeographyMiddle East78,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29GeographyNorth America393,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29GeographySouth America5,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29ProductClinical Lab404,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29ProductContract Manufacturing281,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29ProductOver The Counters329,000USD0001641172-25-004571
    Q3 2024Quarterly · 2024-02-29ProductPhysicians Office3,000USD0001641172-25-004571
    FY 2023Yearly · 2023-05-31GeographyAsia2,021,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31GeographyEurope1,798,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31GeographyMiddle East39,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31GeographyNorth America1,470,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31GeographySouth America11,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31ProductClinical Lab3,310,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31ProductContract Manufacturing610,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31ProductOver The Counte1,169,000USD0001493152-24-034208
    FY 2023Yearly · 2023-05-31ProductPhysicians Office250,000USD0001493152-24-034208
    Q3 2023Quarterly · 2023-02-28SegmentClinical Lab532,000USD0001513162-23-000067
    Q3 2023Quarterly · 2023-02-28SegmentContract Manufacturing284,000USD0001513162-23-000067

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.